The First Multi-Site Clinical Trial for IH and Type 2 Narcolepsy in the US Is Underway

The First Multi-Site Clinical Trial for IH and Type 2 Narcolepsy in the US Is Underway

ARISE 201 is the first double-blind, placebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults.

More than 20 study sites throughout the United States are currently prescreening or screening people with IH and T2N for enrollment, with some sites already having enrolled participants. Additional sites are on target to begin enrolling participants in the coming months.

If you are interested in finding out more about this study, please visit http://www.arisestudies.com/ or click on this link to the study on clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT02512588).

 arise



Get SomnusNooze, our e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive and email from (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. Thank you for your interest in Hypersomnia Foundation!